We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hi-Crush (HCLP) Inks Frac Sand Deal With Chesapeake Energy
Read MoreHide Full Article
Hi-Crush Partners LP inked a new, long-term frac sand supply deal for the in-basin purchase of Northern White frac sand.
The move will support Chesapeake Energy Corporation (CHK - Free Report) and its completions program in the Marcellus and Powder River Basins. Additionally, Chesapeake will utilize one PropStream container crew and associated logistics. Based on demand, the company has the option to expand.
According to Hi-Crush, the deal will address Chesapeake’s demand for Northern White frac sand and related proppant logistics requirements. It also affirms the strength of the company’s logistics network and success in partnering with producer customers.
Hi-Crush’s shares have slumped 48.6% in the past three months compared with the industry’s decline of 1.2%.
The company delivered profit of $26.5 million or 29 cents per share in third-quarter 2018, down from $29.8 million or 32 cents in the year-ago quarter. Adjusted earnings came in at 36 cents, which beat the Zacks Consensus Estimate of 31 cents.
Revenues jumped roughly 27.7% year over year to $214 million. The figure marginally surpassed the Zacks Consensus Estimate of $212.4 million.
Hi-Crush witnessed rapid change in market conditions in the frac sand sector during the third quarter, which led to declines in well completion activity and frac sand demand. The change also affected the market for Northern White pricing and volumes, which is expected to continue in the fourth quarter.
The partnership expects total sales volumes for the fourth quarter in the range of 2.3-2.5 million tons. Notably, total volumes sold in the fourth quarter are likely to be affected by persistent weakness in completions activity along with typical seasonal slowdowns. The partnership expects completions activity to increase in 2019 along with improving demand and supply dynamics for frac sand.
Methanex has an expected long-term earnings growth rate of 15%. Its shares have rallied 25.7% in a year’s time.
Mosaic has an expected long-term earnings growth rate of 7%. The company’s shares have rallied 57.9% in the past year.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
Image: Bigstock
Hi-Crush (HCLP) Inks Frac Sand Deal With Chesapeake Energy
Hi-Crush Partners LP inked a new, long-term frac sand supply deal for the in-basin purchase of Northern White frac sand.
The move will support Chesapeake Energy Corporation (CHK - Free Report) and its completions program in the Marcellus and Powder River Basins. Additionally, Chesapeake will utilize one PropStream container crew and associated logistics. Based on demand, the company has the option to expand.
According to Hi-Crush, the deal will address Chesapeake’s demand for Northern White frac sand and related proppant logistics requirements. It also affirms the strength of the company’s logistics network and success in partnering with producer customers.
Hi-Crush’s shares have slumped 48.6% in the past three months compared with the industry’s decline of 1.2%.
The company delivered profit of $26.5 million or 29 cents per share in third-quarter 2018, down from $29.8 million or 32 cents in the year-ago quarter. Adjusted earnings came in at 36 cents, which beat the Zacks Consensus Estimate of 31 cents.
Revenues jumped roughly 27.7% year over year to $214 million. The figure marginally surpassed the Zacks Consensus Estimate of $212.4 million.
Hi-Crush witnessed rapid change in market conditions in the frac sand sector during the third quarter, which led to declines in well completion activity and frac sand demand. The change also affected the market for Northern White pricing and volumes, which is expected to continue in the fourth quarter.
The partnership expects total sales volumes for the fourth quarter in the range of 2.3-2.5 million tons. Notably, total volumes sold in the fourth quarter are likely to be affected by persistent weakness in completions activity along with typical seasonal slowdowns. The partnership expects completions activity to increase in 2019 along with improving demand and supply dynamics for frac sand.
Hi-Crush Partners LP Price and Consensus
Hi-Crush Partners LP Price and Consensus | Hi-Crush Partners LP Quote
Zacks Rank & Stocks to Consider
Hi-Crush currently carries a Zacks Rank #5 (Strong Sell).
A few better-ranked stocks in the basic materials space are Methanex Corporation (MEOH - Free Report) and The Mosaic Company (MOS - Free Report) , both sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Methanex has an expected long-term earnings growth rate of 15%. Its shares have rallied 25.7% in a year’s time.
Mosaic has an expected long-term earnings growth rate of 7%. The company’s shares have rallied 57.9% in the past year.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
See them today for free >>